Literature DB >> 15125510

Surgical option for nonmelanoma skin cancer.

Patricia Pichardo-Velázquez1, Judith Domínguez-Cherit, M a Elisa Vega-Memije, Gabriela Moreno-Coutiño, Héctor Proy.   

Abstract

BACKGROUND: Basal cell carcinoma (BCC) is one of the most frequent malignancies in the general population. Its best treatment option is the complete excision of the lesion. Mohs' micrographic surgery has demonstrated to be the surgical method with the highest cure rates, however, it is not available in many countries or institutions.
METHODS: We propose, as a treatment option for high-risk BCC, surgical resection of the tumor with transoperatory histological examination with the hematoxilin-eosin technique, delaying closure of the wounds until the margins and surgical bed are tumor-free.
RESULTS: We studied 83 patients with BCC; 49 were treated with the transoperatory technique and delay closure. We observed no recurrence in any patient that we followed up and there were no complications resulting from the technique in a 25-month follow up.
CONCLUSIONS: We recommend this technique for tumors with high-risk of recurrence if Mohs' micrographic surgery is not available.

Entities:  

Mesh:

Year:  2004        PMID: 15125510     DOI: 10.1111/j.1365-4632.2004.02091.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  3 in total

1.  [Experiences with surgical management of facial basal cell carcinoma and procedures for plastic reconstruction].

Authors:  J Rustemeyer; V Thieme; L Günther; A Bremerich
Journal:  Mund Kiefer Gesichtschir       Date:  2005-07

Review 2.  Surgical treatment of basal cell carcinoma: an algorithm based on the literature.

Authors:  Flávio Barbosa Luz; Camila Ferron; Gilberto Perez Cardoso
Journal:  An Bras Dermatol       Date:  2015-06-01       Impact factor: 1.896

3.  Analysis of effectiveness of a surgical treatment algorithm for basal cell carcinoma.

Authors:  Flávio Barbosa Luz; Camila Ferron; Gilberto Perez Cardoso
Journal:  An Bras Dermatol       Date:  2016 Nov-Dec       Impact factor: 1.896

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.